Bristol-Myers Squibb has completed a major expansion at its Devens, MA biologics facility designed to accelerate development of the company’s biologics portfolio  
 
The $280 million investment adds new capabilities with a biologics development building for designing processes for the early production of investigational medicines, and a clinical manufacturing building to produce products to support clinical trials. The Devens site had previously focused solely on large-scale, bulk biologics manufacturing.
 
“Biologics are increasingly important in the treatment of serious diseases and a rapidly growing part of our company’s pipeline of potential new therapies,” said Lou Schmukler, president, Global Manufacturing & Supply. “Bringing together biologics development and clinical and commercial manufacturing on one campus will help accelerate the development of these innovative medicines for patients worldwide.”
 
The expansion initially adds 200 new jobs, and is expected to grow to approximately 350 over time. The two new buildings add approximately 200,000 sq.-ft. to the Devens site, which now comprises eight major buildings in a 600,000 sq.-ft. complex.  
 
“This project represents a significant expansion in the site’s size and mission,” said Greg Guyer, senior vice president, Biologics Development and Operations. “It creates one of the world’s premier integrated biologics facilities, a biologics center of excellence for the company, for the Commonwealth of Massachusetts, and for patients.”